Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances in EZH2-based dual inhibitors in the treatment of cancers
Xiaojuan Yang, Xu Lu, Yang Li
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115461-115461
Closed Access | Times Cited: 13

Showing 13 citing articles:

Inhibition of the histone methyltransferase EZH2 induces vascular stiffness
Jaime Ibarrola, Rachel R. Xiang, Zhe Sun, et al.
Clinical Science (2024) Vol. 138, Iss. 5, pp. 251-268
Open Access | Times Cited: 5
Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities
Michał Woźniak, Małgorzata Czyż
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Computational exploration in search for novel natural product-derived EZH2 inhibitors for advancing anti-cancer therapy
Sagar Singh Shyamal
Molecular Diversity (2025)
Closed Access
Proteogenomic discovery of RB1 -defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets
Jacopo Iacovacci, Rachel Brough, Fatemeh Ahmadi Moughari, et al.
Science Advances (2025) Vol. 11, Iss. 13
Closed Access
Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy
Xinxin Li, Cheng Wang, Shang Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116054-116054
Closed Access | Times Cited: 8
Epigallocatechin-3-gallate inhibit the protein arginine methyltransferase 5 and Enhancer of Zeste homolog 2 in breast cancer bothin vitroandin vivo
Kirankumar Nalla, Biji Chatterjee, Jagadeesha Poyya, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Morphological Changes Induced by TKS4 Deficiency Can Be Reversed by EZH2 Inhibition
Mevan Jacksi, Éva Schád, Ágnes Tantos
(2024)
Open Access | Times Cited: 1
Morphological Changes Induced by TKS4 Deficiency Can Be Reversed by EZH2 Inhibition in Colorectal Carcinoma Cells
Mevan Jacksi, Éva Schád, Ágnes Tantos
Biomolecules (2024) Vol. 14, Iss. 4, pp. 445-445
Open Access | Times Cited: 1
Design, Synthesis, and Biological Evaluation of Potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer
Mei-Ling Le, Wenhua Lu, Xiaozhuo Tan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 15586-15605
Closed Access | Times Cited: 1
Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies
Tahereh Hojjatipour, Mina Ajeli, Amirhosein Maali, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104498-104498
Closed Access
Covalent inhibitors meet epigenetics: new opportunities
Qiang Feng, Luoting Yu, Li Lu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116951-116951
Closed Access
Epigallocatechin gallate inhibit the protein arginine methyltransferase 5 and Enhancer of Zeste homolog 2 in breast cancer both in vitro and in vivo
Kirankumar Nalla, Biji Chatterjee, Jagadeesha Poyya, et al.
Archives of Biochemistry and Biophysics (2024) Vol. 763, pp. 110223-110223
Closed Access
cMYC-mediated immune repression is reversed by inhibition of H3K9/H3K27 methylation maintenance
Isabel CA Dye, Sarah Laing, Ian Garner, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top